Characterization of <i>TP53</i> mutations in actionable driver-negative non-small cell lung cancer (NSCLC).
Jie Chi(Wayne State University), Hirva Mamdani(Wayne State University), Andrew Elliott(Caris Life Sciences (United States)), Ari M. Vanderwalde(West Cancer Center), Stephen V. Liu(Georgetown University), Nishant Gandhi(Caris Life Sciences (United States)), C. Patrick(Penn State Milton S. Hershey Medical Center), B. Halmos(Albert Einstein College of Medicine)
Cited by 4
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373